IDSA: Earlier introduction of HPV vaccine improves initiation, completion by age 13
Introducing the human papillomavirus (HPV) vaccine at ages 9 to 10 years rather than 11 to 12 years leads to a meaningful difference in initiation and completion of the vaccine series, including initiation and completion by age 13 years, according to a study presented at the annual meeting of the Infectious Diseases Society of America (IDWeek), held from Oct. 21 to 24 in Washington, D.C.
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
How our blood vessels age from within
United Kingdom
-
More than half of children under 5 exposed to hep B exposed via household contact
United Kingdom
-
Rising rates of colorectal cancer found in nearly all age groups
United Kingdom
-
A doctor's take on new menopause guidelines
United Kingdom
-
IDSA: Cabotegravir + rilpivirine long-acting antiretroviral therapy beneficial in HIV
United Kingdom
-
Deep brain stimulation improves new neuron maturation for memory
United Kingdom
-
Summer's produce outbreaks expose gaps in FDA oversight of imported food
United Kingdom
-
Initial treatment for lower back pain is associated with subsequent risk of opioid use disorder and overdose
United Kingdom